Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous infliximab versus adalimumab for prevention of recurrent acute anterior uveitis in ankylosing spondylitis
KCT0007239Phase 4Completed
- Sponsor
- Celltrion
- Start
- Nov 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of infliximab, adalimumab in ankylosing spondylitis (AS), sponsored by Celltrion. Started Nov 2022; status: completed.
02
Drugs
infliximabadalimumab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on KCT0007239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0007239.